High-content data can reveal drivers of underdiagnosed liver and heart disease
MASH and cardiomyopathies are prevalent, underdiagnosed diseases where high-content data holds immense signal for uncovering disease drivers. By applying AI to these complex datasets, we can unlock greater discovery power and reveal novel genetic insights.
in a statement on the AstraZeneca collaboration
D
Daphne Kollerinsitro · Founder
Where it comes from
AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugsWhat the article says
AstraZeneca is paying insitro $40 million upfront to find novel drug targets for liver and heart diseases using artificial intelligence. | AstraZeneca is paying insitro $40 million upfront to find ...
fiercebiotech.com